Pearl River Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Pearl River Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-898	Closed	-$375K	–	640
2024 Q1	$375K	Buy	+898	New	+$380K	0.06%	345
2023 Q1	–	Sell	-8,104	Closed	-$2.34M	–	626
2022 Q4	$2.34M	Buy	+8,104	New	+$2.47M	0.4%	68
2021 Q4	–	Sell	-9,672	Closed	-$1.75M	–	583
2021 Q3	$1.75M	Buy	+9,672	New	+$1.89M	0.48%	57
2020 Q3	–	Sell	-6,671	Closed	-$1.94M	–	473
2020 Q2	$1.94M	Buy	+6,671	New	+$1.81M	0.96%	26
2020 Q1	–	Sell	-1,202	Closed	-$263K	–	734
2019 Q4	$263K	Buy	+1,202	New	+$243K	0.1%	379
2019 Q2	–	Sell	-234	Closed	-$44K	–	473
2019 Q1	$44K	Buy	+234	New	+$43.2K	0.11%	250

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Pearl River Capital's VRTX Position: Q2 2024 in Review

Pearl River Capital sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 898 shares — an estimated $375K sold.

Pearl River Capital first reported a position in VRTX in Q1 2019 and held it in 6 quarters. The position peaked at $2.34M in Q4 2022. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

Pearl River Capital reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Pearl River Capital sold 898 Vertex Pharmaceuticals shares in Q2 2024, an estimated $375K.
Pearl River Capital first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 6 quarters.
Pearl River Capital's Vertex Pharmaceuticals position peaked at $2.34M in Q4 2022.
1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Pearl River Capital's 13F filing for Q2 2024, filed 13 Aug 2024.